Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07043751 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

StatusRecruiting
PhasePhase 1
Started2025-07-15
View on ClinicalTrials.gov ↗

Amendment history

2026-01-18
Study Status, Contacts/Locations v2
Study sites3→19
2025-07-15
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07→confirmed 2025-07-15
Study sitesdetails revised at 3 of 3 sites
2025-06-20
Original filing
TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.
Trial Details
NCT Number NCT07043751
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Malignant Tumors
Enrollment 216 participants
Start Date 2025-07-15
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-21